Physician profile
Mitchell Kutner
NPI 1154826105
$3,260.43
in general payments reported to CMS, 2019-2025
21 companies · $84.46 in 2025
The $84.46 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.57 · 2021: $153 · 2022: $885 · 2023: $1,475 · 2024: $652 · 2025: $84.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,211.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $474.00 | 2020-2024 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $469.60 | 2021-2024 | |
| Abbvie INC. | $379.96 | 2022-2024 | |
| Lilly USA, LLC | $352.65 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Biohaven Pharmaceutical Holding Company LTD. | $192.47 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $192.33 | 2021-2024 | Breztri, Farxiga, Airsupra |
| E.R. Squibb & Sons, L.L.C. | $182.50 | 2024-2025 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.52 | 2022-2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $119.16 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.23 | 2021-2024 | Jardiance |
| Amgen INC. | $117.10 | 2021-2024 | Otezla, Repatha, Prolia |
| Exact Sciences Corporation | $92.75 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $85.14 | 2022-2024 | Leqvio |
| Merck Sharp & Dohme LLC | $80.77 | 2022-2023 | Gardasil 9 |
| Dexcom, INC. | $63.92 | 2023-2024 | Dexcom G6 Transmitter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $61.76 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $50.49 | 2023 | |
| Abbott Laboratories | $36.12 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $25.00 | 2021-2022 | |
| Ibsa Pharma INC. | $22.50 | 2023 | Tirosint, Licart |
| Astellas Pharma US INC | $20.46 | 2023 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Kutner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.